shutterstock_vchal_717193216

Vchal / Shutterstock.com

23 September 2020AmericasSarah Morgan

ERS Genomics appoints vice-president of IP

ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Broad and ERS Genomics both claim victory in latest CRISPR ruling

14 September 2020 The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More on this story

Broad and ERS Genomics both claim victory in latest CRISPR ruling

14 September 2020 The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More on this story

Broad and ERS Genomics both claim victory in latest CRISPR ruling

14 September 2020 The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley

How pharma should prep for the six-bill avalanche from Congress

AstraZeneca unit faces class-action suit over alleged Soliris monopoly

USPTO speeds up patent issuance amid widespread agency changes

Lathrop GPM adds portfolio management specialist

Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

Failure to make findings of fact adds twist to battle over Eliquis in Ireland

Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits